Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Extraction: Advanced Methods00:56

Extraction: Advanced Methods

547
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
547
Ion-Exchange Chromatography01:09

Ion-Exchange Chromatography

792
Ion-exchange chromatography, or IEC, is a technique for separating ions based on their affinity for the stationary phase. The stationary phase is a cross-linked polymer resin with covalently attached ionic functional groups. The functional groups can be either positively charged (cation exchangers) or negatively charged (anion exchangers). A cation exchanger consists of a polymeric anion and active cations, while an anion exchanger is a polymeric cation with active anions. The choice of...
792
Complexation Equilibria: The Chelate Effect01:19

Complexation Equilibria: The Chelate Effect

681
In complexation reactions, metal atoms or cations interact with ligands to form donor-acceptor adducts called metal complexes. Ligands that bind through one donor site are monodentate, ligands with two donor sites are bidentate, and those with more than two donor sites are polydentate ligands. For example, ethylene diamine is a bidentate ligand that binds through two nitrogen donor atoms, forming a five-membered ring. EDTA is a polydentate ligand that binds through four oxygen and two nitrogen...
681
EDTA: Chemistry and Properties01:22

EDTA: Chemistry and Properties

2.2K
Polydentate ligands are most widely used in complexometric titrations because they form more stable complexes with the metal ions than mono- or bidentate ligands due to the chelate effect. Examples of polydentate ligands are ethylenediaminetetraacetic acid (EDTA), crown ethers, and cryptands. The most important feature of optimal polydentate ligands is the ability to form 1:1 complexes in a single-step process. Amino carboxylic acid derivatives are frequently used as complexing agents. EDTA is...
2.2K
Masking and Demasking Agents01:19

Masking and Demasking Agents

2.7K
EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
2.7K
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

156
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
156

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thalassaemia.

Nature reviews. Disease primers·2026
Same author

EIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion-Dependent Thalassemia.

American journal of hematology·2026
Same author

Biologic modulation of ineffective erythropoiesis in thalassemia: mechanisms, clinical practice, and future targets.

Expert opinion on biological therapy·2026
Same author

Addressing Obstetric and Gynecologic Needs in Thalassemia.

O&G open·2026
Same author

Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease.

The New England journal of medicine·2026
Same author

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia.

American journal of hematology·2026

Related Experiment Video

Updated: Sep 17, 2025

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
05:36

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

574

Iron Chelation Therapy.

Maria Domenica Cappellini1, Natalia Scaramellini2,3, Simona Leoni2,3

  • 1SC Medicina ad Indirizzo Metabolico, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. maria.cappellini@unimi.it.

Advances in Experimental Medicine and Biology
|July 2, 2025
PubMed
Summary
This summary is machine-generated.

Iron overload from anemias causes organ damage. Chelation therapy uses iron chelators like deferoxamine, deferiprone, and deferasirox to manage iron levels, but treatment adherence is crucial for success.

Keywords:
DeferasiroxDeferiproneDeferoxamineIron overloadTransfusion-dependent anemias

More Related Videos

Removal of Arsenic Using a Cationic Polymer Gel Impregnated with Iron Hydroxide
08:01

Removal of Arsenic Using a Cationic Polymer Gel Impregnated with Iron Hydroxide

Published on: June 28, 2019

7.6K
Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
11:04

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

9.3K

Related Experiment Videos

Last Updated: Sep 17, 2025

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
05:36

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

574
Removal of Arsenic Using a Cationic Polymer Gel Impregnated with Iron Hydroxide
08:01

Removal of Arsenic Using a Cationic Polymer Gel Impregnated with Iron Hydroxide

Published on: June 28, 2019

7.6K
Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
11:04

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

9.3K

Area of Science:

  • Hematology
  • Toxicology
  • Pharmacology

Background:

  • Iron overload is a severe complication in transfusion-dependent anemias and ineffective erythropoiesis.
  • Excess iron accumulation leads to serious organ damage, including heart failure, liver cirrhosis, and endocrine abnormalities.

Purpose of the Study:

  • To review iron overload complications and current chelation therapy options.
  • To highlight the importance of adherence in successful iron chelation treatment.

Main Methods:

  • Review of available iron chelators: parenteral deferoxamine and oral deferiprone and deferasirox.
  • Discussion of dose adjustment strategies to prevent over-chelation.
  • Exploration of factors influencing patient adherence to lifelong treatment.

Main Results:

  • Three main iron chelators are available, each with specific administration routes and considerations.
  • Effective iron chelation requires careful monitoring and dose adjustments.
  • Adherence is influenced by chelator convenience, tolerability, and psychosocial support.

Conclusions:

  • Iron chelation therapy is essential for managing iron overload in specific anemias.
  • Optimizing treatment outcomes depends on balancing efficacy with patient adherence.
  • A multidisciplinary approach supporting patient well-being is vital for long-term management.